22nd Century Net Income 2011-2018 | XXII

22nd Century net income from 2011 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
22nd Century Annual Net Income
(Millions of US $)
2017 $-13
2016 $-12
2015 $-11
2014 $-16
2013 $-26
2012 $-7
2011 $-1
2010 $-1
22nd Century Quarterly Net Income
(Millions of US $)
Q3 2018 $6
Q2 2018 $-7
Q1 2018 $1
Q4 2017 $-4
Q3 2017 $-3
Q2 2017 $-3
Q1 2017 $-3
Q4 2016 $-3
Q3 2016 $-3
Q2 2016 $-3
Q1 2016 $-3
Q4 2015 $-3
Q3 2015 $-3
Q2 2015 $-1
Q1 2015 $-4
Q4 2014 $-6
Q3 2014 $-3
Q2 2014 $-2
Q1 2014 $-5
Q4 2013 $-8
Q3 2013 $-15
Q2 2013 $-0
Q1 2013 $-3
Q4 2012 $-4
Q3 2012 $-0
Q2 2012 $0
Q1 2012 $-2
Q4 2011 $1
Q3 2011 $-0
Q2 2011 $-1
Q1 2011 $-1
Q4 2010 $0
Sector Industry Market Cap Revenue
Consumer Staples Tobacco Products $0.317B $0.017B
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
Stock Name Country Market Cap PE Ratio
Philip Morris (PM) United States $129.746B 16.36
Altria (MO) United States $91.585B 12.22
British American Tobacco (BTI) United Kingdom $78.250B 0.00
Vector Group (VGR) United States $1.674B 26.71
Universal (UVV) United States $1.432B 12.30
Schweitzer-Mauduit (SWM) United States $1.043B 10.52
Turning Point Brands (TPB) United States $0.758B 25.01